AAPM member John Markman, MD is the lead author of a new study that has found tanezumab, a monoclonal antibody that inhibits nerve activity, provides relief in patients with chronic low back pain, one of the leading reasons why people seek medical care and the number one cause of disability worldwide. Full story.
Share this post
Share on facebook
Share on twitter
Share on linkedin
Share on print
Share on email
